ArticleISRN pharmaceutics2012
Development and stability studies of novel liposomal vancomycin formulations.
Article in ISRN pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Formulation and In Vitro Characterization of Granulocyte-Colony-Stimulating-Factor-Loaded Liposomes: Future Prospective in Reproductive Medicine.International journal of molecular sciences · 2025Article
- HER-2 Receptor and αvβ3 Integrin Dual-Ligand Surface-Functionalized Liposome for Metastatic Breast Cancer Therapy.Pharmaceutics · 2024Article
- Mitochondria-Targeted Liposomes for Drug Delivery to Tumor Mitochondria.Pharmaceutics · 2024Article
- Antibiotic-Loaded Nano-Sized Delivery Systems: An Insight into Gentamicin and Vancomycin.Journal of functional biomaterials · 2024Review
- Fabrication and application of targeted ciprofloxacin nanocarriers for the treatment of chronic bacterial prostatitis.International journal of pharmaceutics: X · 2024Article
- Simvastatin-Encapsulated Topical Liposomal Gel for Augmented Wound Healing: Optimization Using the Box-Behnken Model, Evaluations, and In Vivo Studies.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Recent advances in nanostructured delivery systems for vancomycin.Nanomedicine (London, England) · 2024Review
- Nature vs. Manmade: Comparing Exosomes and Liposomes for Traumatic Brain Injury.The AAPS journal · 2023Review
- Controlling the Evolution of Selective Vancomycin Resistance through Successful Ophthalmic Eye-Drop Preparation of Vancomycin-Loaded Nanoliposomes Using the Active-Loading Method.Pharmaceutics · 2023Article
- Pharmacokinetic and Biomarker Quantification Studies on Vancomycin-Loaded PEGylated Liposomes and Its Potential to Reduce Vancomycin-Induced Kidney Injury: A Rat Study.Pharmaceutics · 2023Article
- Peg-Grafted Liposomes for L-Asparaginase Encapsulation.Pharmaceutics · 2022Article
- Surface-tailoring of emulsomes for boosting brain delivery of vinpocetine via intranasal route:Drug delivery · 2022Article
- Review
- Naturally-Sourced Antibacterial Polymeric Nanomaterials with Special Reference to Modified Polymer Variants.International journal of molecular sciences · 2022Review
- pH-Responsive Liposomes of Dioleoyl Phosphatidylethanolamine and Cholesteryl Hemisuccinate for the Enhanced Anticancer Efficacy of Cisplatin.Pharmaceutics · 2022Article
- Surface-engineered liposomes for dual-drug delivery targeting strategy against methicillin-resistantAsian journal of pharmaceutical sciences · 2022Article
- Ultrasound-Triggered Liposomes Encapsulating Quantum Dots as Safe Fluorescent Markers for Colorectal Cancer.Pharmaceutics · 2021Article
- Preclinical In Vitro Studies with 3D Spheroids to Evaluate Cu(DDC)Pharmaceutics · 2021Article
- Nanobiosystems for Antimicrobial Drug-Resistant Infections.Nanomaterials (Basel, Switzerland) · 2021Review
- Cyanocobalamin Ultraflexible Lipid Vesicles: Characterization and In Vitro Evaluation of Drug-Skin Depth Profiles.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A promising strategy to improve the therapeutic efficiency of antimicrobial agents is targeted therapy. Although vancomycin has been considered a gold standard for the therapy of MRSA pneumonia, clinical failure rates have also been reported owing to its slow, time-dependent bactericidal activity, variable lung tissue penetration and poor intracellular penetration into macrophages. Liposomal encapsulation has been established as an alternative for antimicrobial delivery to infected tissue macrophages and offers enhanced pharmacodynamics, pharmacokinetics and decreased toxicity compared to standard preparations. The aim of the present work is to prepare vancomycin in two different liposomal formulations, conventional and PEGylated liposomes using different methods. The prepared formulations were optimized for their particle size, encapsulation efficiency and physical stability. The dehydration-rehydration was found to be the best preparation method. Both the conventional and PEGylated liposomal formulations were successfully formulated with a narrow particle size and size distribution and % encapsulation efficiency of 9 ± 2 and 12 ± 3, respectively. Both the formulations were stable at 4°C for 3 months. These formulations were successfully used to evaluate for their intracellular killing of MRSA and in vivo pharmacokinetic and bio-distribution studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.